April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
January 2020 in “Juntendo Medical Journal” The document's conclusion cannot be determined as the content is not available.
April 2018 in “Journal of Investigative Dermatology” September 2025 in “Jurnal Penelitian Pendidikan IPA” Two genetic variations in Moa buffalo help them adapt to heat.
November 1968 in “Journal of the American Pharmaceutical Association” March 2025 in “Laboratory Investigation” Mesothelioma of the tunica vaginalis testis is rare, often high-grade, and has a median survival of about 24 months.
September 2023 in “Journal of the American Academy of Dermatology”
July 2025 in “Journal of Investigative Dermatology” AMP-303 safely increases hair growth in men with hair loss.
August 2023 in “Sabuncuoglu Serefeddin Health Sciences” CT60 polymorphism might increase the risk of Alopecia Areata.
5 citations
,
December 2017 in “The Journal of Dermatology” A new gene mutation caused a man's rare skin condition, Schöpf-Schulz-Passarge syndrome.
1 citations
,
April 2012 in “Informa Healthcare eBooks” Some medications for inflammation can cause a condition with scalp rashes and hair loss, often linked to Crohn's disease, and may require treatment changes to prevent permanent hair loss.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
November 2022 in “Piretc” New ways to manage Azerbaijan's oil and gas industry using information technology are being developed.
1 citations
,
January 2012 in “Analytical chemistry, an Indian journal” A reliable method was developed to accurately measure tamsulosin hydrochloride and finasteride in tablets.
10 citations
,
January 2015 in “PubMed”
28 citations
,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
222 citations
,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
1 citations
,
April 2018 in “Journal of Investigative Dermatology” Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
September 2024 in “Journal of the American Academy of Dermatology” 11 citations
,
January 2020 in “Engineered science” April 2025 in “Asian Journal of Surgery”
26 citations
,
February 1998 in “Chemico-Biological Interactions” Scientists identified three genes important for processing certain brain chemicals, thyroid hormones, and medications.
5 citations
,
January 2018 The conclusion is that a new test was created to find substances that affect specific ion channels, and it works well for drug discovery.
9 citations
,
May 2014 in “BMC medical genetics” A woman with a unique syndrome similar to TRPS has a genetic change near the TRPS1 gene, affecting its regulation.
December 2012 in “http://isrctn.org/>” December 2023 in “International Journal of Dermatology” April 2026 in “Clinical and Translational Science” Tofacitinib effectively treats severe alopecia areata, improving hair regrowth and patient satisfaction.
14 citations
,
December 2010 in “Journal of human genetics” A Japanese patient with IFAP syndrome had a severe MBTPS2 gene mutation but showed milder symptoms than previously observed cases.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
April 2010 in “Dermatology Times”